About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Our team
Portfolio
News
Connect
Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors
Article Date
October 28, 2025
This article is featured on another website.
Go to article
Related posts
Browse all articles
September 23, 2026
Chime Biologics and Magic Mirror Biotech Enter Strategic Partnership to Advance AI-Enabled Intelligent Manufacturing Across the Biologics Lifecycle
September 23, 2026
Chime Biologics and Magic Mirror Biotech Enter Strategic Partnership to Advance AI-Enabled Intelligent Manufacturing Across the Biologics Lifecycle
October 9, 2026
Shaping the Next Era of Global Biomanufacturing: Chime Biologics Brings Its “GMP” Vision to CPHI Milan 2026
October 9, 2026
Shaping the Next Era of Global Biomanufacturing: Chime Biologics Brings Its “GMP” Vision to CPHI Milan 2026